Neurocrine Biosciences Gets FDA Breakthrough Therapy Status for Genetic Disorder Treatment
By Ben Glickman
Neurocrine Biosciences has received breakthrough therapy designation for its treatment for congenital adrenal hyperplasia from the U.S. Food and Drug Administration.
The San Diego-based biotechnology company said Tuesday it was on track to submit a new drug application for crinecerfont in the treatment of congenital adrenal hyperplasia, a genetic disorder, in 2024.
The company announced it was on track to advance two gene therapies into the clinic in 2025, and expects to have more than 20 development candidates by 2027.
Chief Medical Officer Eiry Roberts said the FDA designation for crinecerfont was an acknowledgement of the seriousness of congenital adrenal hyperplasia and the unmet need faced by patients.
Breakthrough therapy designation is given by the FDA to speed up development of treatments for serious conditions that show preliminary evidence of effectiveness.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 05, 2023 16:38 ET (21:38 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst